Giotrif
![PC-KR-103061-thumb.png](/kr/sites/default/files/styles/bi_gds_card_style/public/2024-05/PC-KR-103061-thumb.png)
[GIOTRIF] A sequential approach of first-line GIOTRIF® followed by various subsequent treatments can be a feasible and appropriate treatment option for patients with EGFR M+ NSCLC from TOAST study
![over-1000.png](/kr/sites/default/files/styles/bi_gds_card_style/public/2024-05/over-1000.png)
[GIOTRIF] Over 1000 published cases of patients with uncommon EGFR M+ NSCLC treated with GIOTRIF®
![PC-KR-096-thumb.png](/kr/sites/default/files/styles/bi_gds_card_style/public/2023-09/PC-KR-096-thumb.png)
[GIOTRIF] Based on current real-world and clinical trial evidences, the optimal regimen maybe first-line afatinib followed by osimertinib4-
![PC-KR-103096-thumb2.png](/kr/sites/default/files/styles/bi_gds_card_style/public/2023-09/PC-KR-103096-thumb2.png)